Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Clinical trial NCT06203912 · COMPLETED
Trial details
- NCT number
- NCT06203912
- Sponsor
- Elvira Umyarova
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-05
- Primary completion
- 2026-05-19
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.